相关实验视频
Updated: Jun 26, 2025

06:08
Transcranial Pulse Stimulation for Alzheimer's Patients
Published on: April 4, 2025
544
单值大脑活动评分反映了阿尔茨海默氏症连续性中的严重程度和风险
Joram Soch1,2,3, Anni Richter4,5,6, Jasmin M Kizilirmak1,7
1German Center for Neurodegenerative Diseases (DZNE), 37075 Göttingen, Germany.
Brain : a journal of neurology
|May 14, 2024
概括
新性和记忆功能性MRI得分 (FADE和SAME) 在阿尔茨海默病 (AD) 和轻度认知障碍 (MCI) 患者与对照组相比显示出显著差异. 这些得分与认知表现和AD风险因素相关,表明生物标志物的潜力.
科学领域:
- 神经成像是一种神经成像.
- 神经退行性疾病 神经退行性疾病
- 生物标志物发现发现
背景情况:
- 年轻成年人的功能性MRI (fMRI) 激活模式已被用于开发偏差 (FADE) 和相似性 (SAME) 评分.
- 这些分数旨在捕捉新奇性和与记忆相关的大脑活动.
- 它们在阿尔茨海默病 (AD) 和其风险状态中的实用性尚未完全确定.
研究的目的:
- 评估FADE和SAME分数作为潜在的AD和相关认知衰退的诊断和预后成像生物标志物.
- 评估这些分数与AD风险阶段,认知功能和遗传/生化标志物的关联.
主要方法:
- 从DELCODE研究中分析了468名SCD,MCI,AD痴呆症,健康对照和AD亲属 (AD-rel) 参与者的后续记忆fMRI数据.
- 基于新奇性和记忆反应计算全脑FADE和SAME分数.
- 评价与神经心理测试,CSF粉样蛋白状况和APOE基因型的得分相关性.
主要成果:
- 与对照组,SCD和AD相关组相比,MCI和AD痴呆症组在基于记忆的FADE/SAME得分中表现出更大的偏差.
- 基于新性的得分区分了MCI和AD痴呆症组.
- 与整个样本的认知表现相关的得分.
- 基于新性的SAME分数区分了特定子组中的粉样蛋白阳性/阴性和APOE ɛ4载体/非载体个体.
结论:
- FADE和SAME分数与认知表现和个体AD风险因素有关.
- 这些得分显示出作为AD潜在的诊断和预后生物标志物的希望.
- 需要进一步的研究来探索它们的实用性,特别是在主观认知衰退 (SCD) 患者和阿兹海默症患者的健康亲属身上.
更多相关视频
07:30Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
Published on: April 23, 2021
3.0K
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
32.3K
相关概念视频
Alzheimer's Disease: Overview
467
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
467
Alzheimer's Disease: Treatment
181
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
181